Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

18F-choline PET/mpMRI for Detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies.

Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett C, Denton B, Piert M.

J Nucl Med. 2019 Aug 16. pii: jnumed.119.225789. doi: 10.2967/jnumed.119.225789. [Epub ahead of print]

PMID:
31420496
2.

Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.

Eich ML, Chandrashekar DS, Rodriguez Pen A MDC, Robinson AD, Siddiqui J, Daignault-Newton S, Chakravarthi BVSK, Kunju LP, Netto GJ, Varambally S.

Prostate. 2019 Oct;79(14):1629-1639. doi: 10.1002/pros.23887. Epub 2019 Aug 2.

PMID:
31376196
3.

18F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.

Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M.

J Nucl Med. 2019 Jul 26. pii: jnumed.119.225771. doi: 10.2967/jnumed.119.225771. [Epub ahead of print]

PMID:
31350321
4.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

5.

Computer-Aided Laser Dissection: A Microdissection Workflow Leveraging Image Analysis Tools.

Hipp JD, Johann DJ, Chen Y, Madabhushi A, Monaco J, Cheng J, Rodriguez-Canales J, Stumpe MC, Riedlinger G, Rosenberg AZ, Hanson JC, Kunju LP, Emmert-Buck MR, Balis UJ, Tangrea MA.

J Pathol Inform. 2018 Dec 11;9:45. doi: 10.4103/jpi.jpi_60_18. eCollection 2018.

6.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A.

Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18.

7.

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM.

Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.

8.

Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.

Williamson SR, Rao P, Hes O, Epstein JI, Smith SC, Picken MM, Zhou M, Tretiakova MS, Tickoo SK, Chen YB, Reuter VE, Fleming S, Maclean FM, Gupta NS, Kuroda N, Delahunt B, Mehra R, Przybycin CG, Cheng L, Eble JN, Grignon DJ, Moch H, Lopez JI, Kunju LP, Tamboli P, Srigley JR, Amin MB, Martignoni G, Hirsch MS, Bonsib SM, Trpkov K.

Am J Surg Pathol. 2018 Sep;42(9):1253-1261. doi: 10.1097/PAS.0000000000001087.

PMID:
29878933
9.

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM.

Nat Genet. 2018 Jun;50(6):814-824. doi: 10.1038/s41588-018-0120-1. Epub 2018 May 28.

10.

Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.

Chakravarthi BVSK, Goswami MT, Pathi SS, Dodson M, Chandrashekar DS, Agarwal S, Nepal S, Hodigere Balasubramanya SA, Siddiqui J, Lonigro RJ, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S.

Prostate. 2018 Jun;78(9):693-694. doi: 10.1002/pros.23533. Epub 2018 Apr 10. No abstract available.

11.

Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications.

Piert M, Shankar PR, Montgomery J, Kunju LP, Rogers V, Siddiqui J, Rajendiran T, Hearn J, George A, Shao X, Davenport MS.

EJNMMI Res. 2018 Mar 27;8(1):23. doi: 10.1186/s13550-018-0377-5.

12.

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB.

Am J Surg Pathol. 2018 Mar;42(3):279-292. doi: 10.1097/PAS.0000000000001000.

PMID:
29309300
13.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20. Erratum in: J Clin Oncol. 2018 May 20;36(15):1541.

14.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

15.

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.

Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnaiyan AM, de Bono JS.

Clin Cancer Res. 2017 Oct 15;23(20):6070-6077. doi: 10.1158/1078-0432.CCR-17-0972. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2018 May 1;24(9):2234. Chinnaiyan, Arul [corrected to Chinnaiyan, Arul M].

16.

Next generation sequencing of extraskeletal myxoid chondrosarcoma.

Davis EJ, Wu YM, Robinson D, Schuetze SM, Baker LH, Athanikar J, Cao X, Kunju LP, Chinnaiyan AM, Chugh R.

Oncotarget. 2017 Mar 28;8(13):21770-21777. doi: 10.18632/oncotarget.15568.

17.

Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists.

Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Kunju LP, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS.

Hum Pathol. 2017 May;63:149-156. doi: 10.1016/j.humpath.2017.03.004. Epub 2017 Mar 14.

18.

Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer.

Piert M, Shao X, Raffel D, Davenport MS, Montgomery J, Kunju LP, Hockley BG, Siddiqui J, Scott PJH, Chinnaiyan AM, Rajendiran T.

J Nucl Med. 2017 Aug;58(8):1216-1223. doi: 10.2967/jnumed.116.173179. Epub 2017 Mar 16.

19.

Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.

Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS.

Clin Cancer Res. 2017 Feb 15;23(4):985-991. doi: 10.1158/1078-0432.CCR-16-1454. Epub 2016 Oct 7.

20.

Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision?

Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL, Hawken S, Krishnan N, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Palapattu GS, Weizer AZ, Wolf JS Jr.

Urology. 2016 Dec;98:88-96. doi: 10.1016/j.urology.2016.04.067. Epub 2016 Jul 19.

PMID:
27450936
21.

Independent surgical validation of the new prostate cancer grade-grouping system.

Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM.

BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19.

22.

Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs).

Hawken SR, Krishnan NK, Ambani SN, Montgomery JS, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Kutikov A, Palapattu GS, Weizer AZ, Stuart Wolf J, Morgan TM.

Urol Oncol. 2016 Nov;34(11):486.e9-486.e15. doi: 10.1016/j.urolonc.2016.05.032. Epub 2016 Sep 28.

PMID:
27687544
23.

Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.

Chakravarthi BV, Goswami MT, Pathi SS, Dodson M, Chandrashekar DS, Agarwal S, Nepal S, Hodigere Balasubramanya SA, Siddiqui J, Lonigro RJ, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S.

Prostate. 2017 Jan;77(1):10-21. doi: 10.1002/pros.23243. Epub 2016 Aug 22. Erratum in: Prostate. 2018 Jun;78(9):693-694.

24.

MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.

Chakravarthi BV, Goswami MT, Pathi SS, Robinson AD, Cieślik M, Chandrashekar DS, Agarwal S, Siddiqui J, Daignault S, Carskadon SL, Jing X, Chinnaiyan AM, Kunju LP, Palanisamy N, Varambally S.

Oncogene. 2016 Dec 8;35(49):6330-6340. doi: 10.1038/onc.2016.164. Epub 2016 Jun 6.

25.

Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Vs Malignant Disease and Low-risk Vs High-risk Renal Tumors.

Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr.

Urology. 2016 Oct;96:87-92. doi: 10.1016/j.urology.2016.05.044. Epub 2016 Jun 1.

PMID:
27262393
26.

Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up.

Alderman MA, Daignault S, Wolf JS Jr, Palapattu GS, Weizer AZ, Hafez KS, Kunju LP, Wu AJ.

Hum Pathol. 2016 Sep;55:1-10. doi: 10.1016/j.humpath.2016.03.017. Epub 2016 Apr 13.

PMID:
27085554
27.

18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.

Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, Johnson TD, Shao X, Davenport MS.

J Nucl Med. 2016 Jul;57(7):1065-70. doi: 10.2967/jnumed.115.170878. Epub 2016 Mar 16.

28.

ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer.

Lorenzatti Hiles G, Bucheit A, Rubin JR, Hayward A, Cates AL, Day KC, El-Sawy L, Kunju LP, Daignault S, Lee CT, Liebert M, Hussain M, Day ML.

PLoS One. 2016 Mar 1;11(3):e0150138. doi: 10.1371/journal.pone.0150138. eCollection 2016.

29.

Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R.

J Urol. 2016 Aug;196(2):405-11. doi: 10.1016/j.juro.2016.01.120. Epub 2016 Feb 23.

PMID:
26920466
30.

Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.

Xu G, Davis MC, Siddiqui J, Tomlins SA, Huang S, Kunju LP, Wei JT, Wang X.

Biomed Opt Express. 2015 Nov 9;6(12):4781-9. doi: 10.1364/BOE.6.004781. eCollection 2015 Dec 1.

31.

Age, Gender and R.E.N.A.L. Nephrometry Score do not Improve the Accuracy of a Risk Stratification Algorithm Based on Biopsy and Mass Size for Assigning Surveillance versus Treatment of Renal Tumors.

Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr.

J Urol. 2016 Mar;195(3):574-80. doi: 10.1016/j.juro.2015.10.137. Epub 2015 Oct 30.

PMID:
26523883
32.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

33.

ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Palmbos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins SA, Daignault S, Kunju LP, Wu XR, Lotan Y, Liebert M, Ljungman ME, Simeone DM.

Cancer Res. 2015 Dec 1;75(23):5155-66. doi: 10.1158/0008-5472.CAN-15-0603. Epub 2015 Oct 15.

34.

Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.

Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R.

Med Oncol. 2015 Nov;32(11):249. doi: 10.1007/s12032-015-0693-9. Epub 2015 Oct 6.

PMID:
26442515
35.

Intraductal Carcinoma of the Prostate: Morphologic Features, Differential Diagnoses, Significance, and Reporting Practices.

Magers M, Kunju LP, Wu A.

Arch Pathol Lab Med. 2015 Oct;139(10):1234-41. doi: 10.5858/arpa.2015-0206-RA. Review.

PMID:
26414467
36.

A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall.

McDaniel AS, Palanisamy N, Smith SC, Robinson DR, Wu YM, Chinnaiyan AM, McHugh JB, Greenson JK, Kunju LP.

Histol Histopathol. 2016 Feb;31(2):223-30. doi: 10.14670/HH-11-670. Epub 2015 Sep 26.

PMID:
26404914
37.

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM.

JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080.

38.

The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.

Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, Palanisamy N, Siddiqui J, Cao X, Su F, Wang R, Xiao H, Kunju LP, Mehra R, Tomlins SA, Fullen DR, Bichakjian CK, Johnson TM, Dlugosz AA, Chinnaiyan AM.

Cancer Res. 2015 Sep 15;75(18):3720-3727. doi: 10.1158/0008-5472.CAN-15-0702. Epub 2015 Aug 3.

39.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

40.

Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among Urologic Pathologists With Recommendations.

Zhou M, Li J, Cheng L, Egevad L, Deng FM, Kunju LP, Magi-Galluzzi C, Melamed J, Mehra R, Mendrinos S, Osunkoya AO, Paner G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang X, Shah RB.

Am J Surg Pathol. 2015 Oct;39(10):1331-9. doi: 10.1097/PAS.0000000000000457.

PMID:
26099009
41.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

42.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

43.

Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: an interobserver reproducibility study among urologic pathologists.

Shah RB, Li J, Cheng L, Egevad L, Deng FM, Fine SW, Kunju LP, Melamed J, Mehra R, Osunkoya AO, Paner GP, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, Zhou M.

Am J Surg Pathol. 2015 Sep;39(9):1242-9. doi: 10.1097/PAS.0000000000000442.

PMID:
25929349
44.

Targeting the MLL complex in castration-resistant prostate cancer.

Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM.

Nat Med. 2015 Apr;21(4):344-52. doi: 10.1038/nm.3830. Epub 2015 Mar 30.

45.

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N.

Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23.

46.

Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.

Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng FY, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, Palapattu GS, Mehra R.

Asian J Urol. 2015 Jan;2(1):53-58. doi: 10.1016/j.ajur.2015.04.007. Epub 2015 Apr 16.

47.

Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features.

Wu AJ, Mehra R, Hafez K, Wolf JS Jr, Kunju LP.

Histopathology. 2015 Mar;66(4):587-97. doi: 10.1111/his.12524. Epub 2014 Dec 22.

48.

Inflammatory myofibroblastic tumor of the bladder.

Alderman M, Kunju LP.

Arch Pathol Lab Med. 2014 Oct;138(10):1272-7. doi: 10.5858/arpa.2014-0274-CC. Review.

PMID:
25268188
49.

Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.

Kunju LP, Carskadon S, Siddiqui J, Tomlins SA, Chinnaiyan AM, Palanisamy N.

Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):e32-40. doi: 10.1097/PAI.0000000000000095.

50.

Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.

Palanisamy N, Tsodikov A, Yan W, Suleman K, Rittmaster R, Lucia SM, Chinnaiyan AM, Fleshner N, Kunju LP.

Urol Oncol. 2015 Mar;33(3):108.e5-13. doi: 10.1016/j.urolonc.2014.07.015. Epub 2014 Aug 28.

PMID:
25175425

Supplemental Content

Loading ...
Support Center